Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CTLA4 monoclonal antibody GIGA-564

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4; CTLA4; CD152), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody GIGA-564 targets and binds to CTLA-4, and may induce Fc receptor (FcR) signaling. This may deplete regulatory T cells (Tregs) in the tumor microenvironment (TME), decrease the proliferation of the remaining Tregs in the TME, and reactivate antitumor immune responses. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system. GIGA-564 has limited checkpoint inhibitory activity as it only weakly blocks the interaction between CTLA-4 and its B7 ligands CD80 and CD86.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:GIGA 564
GIGA-564
GIGA564
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search